Abstract

The stimulating Editorial by Datzmann et al . (1) suggests further considerations on the prognostic parameters for patients on veno venous extracorporeal membrane oxygenation (VV ECMO) support. While VV ECMO is increasingly acknowledged as a life-saving therapeutic tool for refractory acute respiratory distress syndrome (ARDS) especially in high volume and experienced centers, it is also is associated with elevated costs, resource, and complications (2) and appropriate risk stratification of candidate patients is necessary to recognize those more likely to benefit from VV ECMO (3). Moreover, in everyday practice, an objective risk assessment for refractory ARDS on ECMO support is a clinical need for intensivists also to provide relatives with information about the patient’s condition.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.